Reata Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting of Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome

PLANO, Texas--(BUSINESS WIRE) December 8, 2021 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the“Company,” or“we”), today announced the outcome of the U.S. Food and Drug Administration...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news